Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of two dosing regimens of a compound known
as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid
arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
Trubion Pharmaceuticals/Emergent BioSolutions Inc.